Immunogenicity and safety of HBAI20 Hepatitis B vaccine in non-responders: Double-blinded, randomised, controlled phase 2 trial.
Özgür Muhammet KocPhilippe de SmedtCécile KremerGeert RobaeysPierre van DammeNiel HensJorge AlmeidaFrank FalkenbergPaul SavelkoulAstrid Oude Lashofnull nullPublished in: Liver international : official journal of the International Association for the Study of the Liver (2021)
In this group of hepatitis B vaccine non-responders, the HBAI20 vaccine demonstrated a higher seroprotection rate when adjusting for stratification factors and a similar safety profile compared to the licensed recombinant HBVaxPro®-10 µg.
Keyphrases